PDX Portal

Model Details

Patient Information for Model: BCM-PDAC-18

Model Contact

Model: BCM-PDAC-18
Model Contact: Qizhi Cathy Yao
Institution: BCM Pancreas PDX Program
Email: qizhiyao@bcm.edu

Patient Information

Clinical Timeline

Clinical Information at Collection

Clinical Biomarkers/Mutations at Collection

Pathology Information at Collection

Model Information for Model: BCM-PDAC-18

Model Details - Initial Implantation of Patient Tissue

Mutations (Cancer Gene Census List)

GeneFilter by Gene	ChrFilter by Chr	Start	End	Ref	Alt	cDNA Change	Codon Change	Protein Change	TVAF	Gene Mutation Freq.	Site Mutation Freq.	Most Severe Effect	All Effects	Mutation Impact	Transcript ID	ClinVar Clinical Significance	COSMIC ID	gnomAD Non-Cancer AF	dbSNP ID	Gene Mutation Freq.	Site Mutation Freq.	Transcript ID	ClinVar Clinical Significance	COSMIC ID	dbSNP ID
A1CF	chr10	50814012	50814012	C	T	c.1168G>A	Ggc/Agc	p.G390S	0.384	4	4	Missense Variant	Missense Variant	MODERATE	ENST00000373997.8	Likely_benign		0.005167690000	rs41274050	4	4	ENST00000373997.8	Likely_benign		rs41274050
ACVR1	chr2	157770418	157770418	C	A	c.740G>T	aGg/aTg	p.R247M	0.123	3	3	Missense Variant	Missense Variant	MODERATE	ENST00000434821.7					3	3	ENST00000434821.7
AKAP9	chr7	92022864	92022864	A	AAAC	c.4004_4006dup	aaa/aAACaa	p.K1335_L1336insQ	0.459	15	13	In-frame Insertion	In-frame Insertion	MODERATE	ENST00000356239.8		COSV62337888		rs10644111	15	13	ENST00000356239.8		COSV62337888	rs10644111
AKAP9	chr7	92099813	92099813	A	G	c.10840A>G	Atg/Gtg	p.M3614V	0.208	15	4	Missense Variant	Missense Variant	MODERATE	ENST00000356239.8	Benign/Likely_benign	COSV99072410	0.006949960000	rs34327395	15	4	ENST00000356239.8	Benign/Likely_benign	COSV99072410	rs34327395
ATRX	chrX	77682471	77682471	C	G	c.2785G>C	Gag/Cag	p.E929Q	0.499	20	20	Missense Variant	Missense Variant	MODERATE	ENST00000373344.10	Benign			rs3088074	20	20	ENST00000373344.10	Benign		rs3088074
AXIN2	chr17	65537614	65537614	A	ATGG	c.1419_1421dup	cat/caCCAt	p.H474dup	0.366	8	4	In-frame Insertion	In-frame Insertion	MODERATE	ENST00000307078.10		COSV100195931			8	4	ENST00000307078.10		COSV100195931
BRCA1	chr17	43093819	43093819	A	G	c.1712T>C	aTa/aCa	p.I571T	0.5	6	4	Missense Variant	Missense Variant	MODERATE	ENST00000357654.9	Conflicting_interpretations_of_pathogenicity		0.000012699200	rs80357159	6	4	ENST00000357654.9	Conflicting_interpretations_of_pathogenicity		rs80357159
CIC	chr19	42293072	42293072	G	A	c.3586G>A	Gcc/Acc	p.A1196T	0.37	5	4	Missense Variant	Missense Variant	MODERATE	ENST00000575354.6			0.000114452000	rs199898619	5	4	ENST00000575354.6			rs199898619
CIITA	chr16	10909070	10909070	A	G	c.2702A>G	cAg/cGg	p.Q901R	0.993	24	24	Missense Variant	Missense Variant	MODERATE	ENST00000618327.4	Benign		0.983235000000	rs7197779	24	24	ENST00000618327.4	Benign		rs7197779
CREBBP	chr16	3769232	3769246	GTCTCCGTCTTCATT	G	c.2988_3001del	gaAATGAAGACGGAGAcc/gacc	p.E996Dfs*7	0.063	3	3	Frameshift Mutation	Frameshift Mutation	HIGH	ENST00000262367.10					3	3	ENST00000262367.10
CTNNA2	chr2	80555765	80555765	G	A	c.1613G>A	cGg/cAg	p.R538Q	0.146	8	4	Missense Variant	Missense Variant	MODERATE	ENST00000402739.8		COSV58141983	0.000026696300	rs374311367	8	4	ENST00000402739.8		COSV58141983	rs374311367
CTNNB1	chr3	41224622	41224622	C	T	c.110C>T	tCt/tTt	p.S37F	0.477	4	4	Missense Variant	Missense Variant	MODERATE	ENST00000349496.11	Pathogenic/Likely_pathogenic	COSV62687856		rs121913403	4	4	ENST00000349496.11	Pathogenic/Likely_pathogenic	COSV62687856	rs121913403
ELL	chr19	18446782	18446782	G	C	c.1498C>G	Ccc/Gcc	p.P500A	0.285	4	4	Missense Variant	Missense Variant	MODERATE	ENST00000262809.9			0.000954352000	rs151228060	4	4	ENST00000262809.9			rs151228060
EP300	chr22	41125999	41125999	A	G	c.865A>G	Atg/Gtg	p.M289V	0.68	8	4	Missense Variant	Missense Variant	MODERATE	ENST00000263253.9	Benign/Likely_benign	COSV105840063	0.001962950000	rs2230111	8	4	ENST00000263253.9	Benign/Likely_benign	COSV105840063	rs2230111
EP300	chr22	41172502	41172502	A	AT	c.4461dup	att/aTtt	p.K1488*	0.5	8	4	Frameshift Mutation	Frameshift Mutation	HIGH	ENST00000263253.9		COSV54325264			8	4	ENST00000263253.9		COSV54325264

CNV

Histology Information for Model: BCM-PDAC-18

There are no histology images for this model.

Metastasis Information for Model: BCM-PDAC-18

Patient

PDX

Liver

Local recurrence

Lung

Rectum

lymph node

Patient Treatment Information for Model: BCM-PDAC-18

Event Id	Treatment	Treatment Setting	Age at Start	Age at End	Duration	Clinical Response	Pathologic Response	Reason Stopped
15	Gemcitabine/Abraxane	Neoadjuvant	65.06	65.2	51 days	Stable Disease (SD); "NO" progression of disease	No Response (NR)	Completed regimen
25	Gemcitabine	Adjuvant	65.75	66.15	146 days	Stable Disease (SD); Rising CA19-9		Completed regimen
30	Capecitabine	Adjuvant	67.16	67.64	175 days	Stable Disease (SD)		Completed regimen
40	Gemcitabine/Abraxane	Adjuvant	68.26	68.49	84 days	Progressive Disease (PD)		Patient transferred to other hospital